Townsquare Capital LLC Sells 7,540 Shares of AbbVie Inc. $ABBV

Townsquare Capital LLC decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 17.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 36,383 shares of the company’s stock after selling 7,540 shares during the quarter. AbbVie accounts for about 1.3% of Townsquare Capital LLC’s investment portfolio, making the stock its 16th biggest position. Townsquare Capital LLC’s holdings in AbbVie were worth $8,424,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Argent Advisors Inc. boosted its holdings in AbbVie by 19.3% during the 3rd quarter. Argent Advisors Inc. now owns 2,805 shares of the company’s stock valued at $649,000 after acquiring an additional 453 shares during the period. Trifecta Capital Advisors LLC lifted its position in shares of AbbVie by 2.3% during the third quarter. Trifecta Capital Advisors LLC now owns 39,928 shares of the company’s stock worth $9,245,000 after purchasing an additional 900 shares during the last quarter. Cahill Financial Advisors Inc. boosted its stake in shares of AbbVie by 8.2% during the third quarter. Cahill Financial Advisors Inc. now owns 3,046 shares of the company’s stock valued at $705,000 after purchasing an additional 231 shares during the period. Knights of Columbus Asset Advisors LLC grew its holdings in shares of AbbVie by 121.3% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 2,700 shares of the company’s stock worth $625,000 after purchasing an additional 1,480 shares during the last quarter. Finally, Asset Allocation & Management Company LLC purchased a new position in AbbVie in the 3rd quarter worth about $219,000. 70.23% of the stock is owned by institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Investor enthusiasm around a reported bispecific trial win and management’s renewed R&D pledge — this strengthens AbbVie’s pipeline narrative and long-term growth prospects. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Retrospective coverage highlighting AbbVie’s strong 2025 performance reinforces confidence in management’s handling of patent cliffs and portfolio transitions. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Allergan Aesthetics unveiled new clinical and portfolio data that support continued strength in the aesthetics business — a valuable, higher-margin growth pillar for AbbVie. Allergan Aesthetics Unveils New Data Across Facial Injectables
• Positive Sentiment: On-air analyst commentary recommended staying long ABBV, adding short-term buying pressure from retail and institutional viewers. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Neutral Sentiment: Coverage of AbbVie’s drug affordability deal notes management is trying to balance price/access commitments with continued R&D and patient-growth plans — reduces regulatory risk but may cap pricing upside. AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans
• Neutral Sentiment: Investor note questioning whether recent gains leave ABBV fairly priced based on DCF and price-to-sales signals — flags valuation scrutiny even as shares rally. Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains
• Neutral Sentiment: AbbVie launched a migraine-focused awareness program (“Love in Mind”) — positive for brand, patient engagement and uptake of migraine therapies but largely a longer-term marketing play. AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine
• Negative Sentiment: Near-term earnings preview from Zacks suggests AbbVie may lack the setup for an earnings beat next week, which could increase volatility if guidance or execution disappoints. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie Stock Up 0.8%

Shares of AbbVie stock opened at $220.42 on Friday. The company has a 50 day moving average price of $224.67 and a 200 day moving average price of $218.02. The firm has a market capitalization of $389.56 billion, a P/E ratio of 166.98, a PEG ratio of 0.90 and a beta of 0.36. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the business earned $3.00 EPS. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ABBV has been the subject of several research reports. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. JPMorgan Chase & Co. boosted their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a report on Thursday, January 15th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $249.37.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.